Dopamine D2/3 Receptor Availability

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Dopamine D2/3 Receptor Availability trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 4

NCT06763172

Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI

This research study aims to determine whether and how caffeine intake affects learning process through reward feedback compared to placebo. The data acquired fr…

United States12 participantsStarted 2023-05-17

Treatment: Caffeine (200 mg), Placebo

All recent trials (3 shown)

Active — Not RecruitingNot Applicable

NCT03911726

Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia

The aim of the present study is to detect changes in the dopamine system in the brain of patients with schizophrenia, especially when pretreated with antipsycho…

Germany140 participantsStarted 2020-08-01

Treatment: Single PET/MR-measurement

TerminatedPhase 1

NCT03059563

Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users

While deficits in dopamine D2-type receptor availability have been linked to substance use disorders, higher availability associates with better behavioral trea…

United States62 participantsStarted 2018-01-11

Treatment: Varenicline, Placebo